Novo Nordisk closes deal on technology platform

Novo Nordisk and SomaLogic have entered into a partnership which allows Novo Nordisk to use the technology platform Somascan in connection with the development of pharmaceutical drugs, while the Danish pharmaceutical company will deliver proteins for the platform.

Photo: Stine Tidsvilde

The collaborative agreement between Novo Nordisk and the global company SomaLogic means that the Danish pharmaceutical company can use the technology platform SomaScan for the development of treatments, for example (NASH), cardiovascular diseases and diabetes, according to a SomaLogic press release.

According to SomaLogic, the technology platform could potentially identify new biomarkers, novel drug targets and improve the assessment and management of therapeutic responses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs